Chang, MH; Barbar-Smiley, F; Akoghlanian, S; Drew, J; Angeles-Han, ST; Quinlan-Waters, M; Bohnsack, JF; Cooper, AM; Edelheit, B; Twachtman-Bassett, J; Stern, S; Sterba Rakovchik, Y; Stephens, A; Steigerwald, K. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology Online Journal. 2024; 22:88.

Brunner, HI; Schulert, GS; Sproles, A; Thornton, S; Cornejo, GV; Antón, J; Cuttica, R; Henrickson, M; Foeldvari, I; Kingsbury, DJ; Lovell, DJ; Martini, A; Ruperto, N; Grom, AA. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research and Therapy. 2024; 26:125.

Gulick, RM; Pau, AK; Daar, E; Evans, L; Gandhi, RT; Tebas, P; Ridzon, R; Masur, H; Lane, HC; Aberg, J; Uyeki, TM; Waghmare, AA; Wolfe, CR; Yazdany, J. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Annals of Internal Medicine. 2024; 177:1547-1557.

Brunner, HI; Akikusa, JD; Al-Abadi, E; Bohnsack, JF; Boteanu, AL; Chedeville, G; Cuttica, R; De La Pena, W; Jung, L; Kasapcopur, O; Liu, S; Martini, A; Lovell, DJ; Ruperto, N. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83:1561-1571.

Correia Marques, M; Ombrello, MJ; Schulert, GS. New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology. 2024; 20:1053-1064.

Lovell, DJ; Tzaribachev, N; Henrickson, M; Simonini, G; Griffin, TA; Alexeeva, E; Bohnsack, JF; Zeft, A; Horneff, G; Vehe, RK; Costanzo, D; Rennebohm, R; Waugaman, B; Brodus, E. Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63:SI195-SI206.

Mannion, ML; Amin, S; Balevic, S; Chang, ML; Correll, CK; Kearsley-Fleet, L; Hyrich, KL; Beukelman, T; Aamir, R; Abulaban, K; DeSantis, E; Devine, R; Dhalla, M; Dhanrajani, A. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76:1090-1098.

Huang, Y; Sompii-Montgomery, L; Patti, J; Pickering, A; Yasin, S; Do, T; Baker, E; Gao, D; Abdul-Aziz, R; Behrens, EM; Ting, T; Grom, AA; Towe, C; Schulert, GS. Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76:328-339.

Schulert, G; Vastert, SJ; Grom, AA. The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.

Grom, AA; Canna, SW; Abu-Arja, RF; Sinha, R; Peixoto, L; Cannizzaro, E; Chandrakasan, S; Driest, K; Marsh, R; Neven, B; Schulert, G; Silva, JM F; Wall, D; Zeilhofer, U. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.

Schulert, GS; Zhang, K. Genetics of Acquired Cytokine Storm Syndromes : Secondary HLH Genetics. Advances in Experimental Medicine and Biology. 2024; 1448:103-119.

Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; Schulert, GS; Grom, AA; Van Loosdregt, J; Vastert, SJ. Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.

Heshin-Bekenstein, M; Baron, S; Schulert, G; Shusterman, A; Fidel, V; Ben-Shahar, Y; Shukrun, R; Binenbaum, Y; Elhasid, R. Neutrophils extracellular traps formation may serve as a biomarker for disease activity in oligoarticular juvenile idiopathic arthritis: a pilot study. Arthritis Research and Therapy. 2023; 25:135.

Inoue, N; Schulert, GS. Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Research and Therapy. 2023; 25:48.

Rao, S; Jing, N; Liu, X; Lorman, V; Maltenfort, M; Schuchard, J; Wu, Q; Tong, J; Razzaghi, H; Mejias, A; Christakis, DA; Bailey, LC; Forrest, CB; Chen, Y. Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program. Scientific Reports. 2023; 13:21005.

Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.

Woo, JM P; Simmonds, F; Dennos, A; Son, MB F; Lewandowski, LB; Rubinstein, TB. Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:2285-2294.

Towe, C; Grom, AA; Schulert, GS. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.

Schulert, GS; Kessel, C. Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America. 2023; 49:895-911.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; de Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.

Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; De Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

Chen, L; Mamutova, A; Kozlova, A; Latysheva, E; Evgeny, F; Latysheva, T; Savostyanov, K; Pushkov, A; Zhanin, I; Raykina, E; Nigrovic, PA; Shcherbina, A; Alexeeva, E; Lee, PY. Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2. Journal of Allergy and Clinical Immunology. 2023; 152:771-782.

Rai, S; Schulert, GS; Towe, C. New developments related to lung complications in pediatric rheumatic disease. Current Opinion in Rheumatology. 2023; 35:273-277.

Mansfield, LM; Lapidus, SK; Romero, SN; Moorthy, LN; Adler-Shohet, FC; Hollander, M; Cherian, J; Twilt, M; Lionetti, G; Mohan, S; Onel, KB; Dedeoglu, F; Guttierez, MJ; Schulert, G. Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America. Frontiers in Pediatrics. 2023; 11:1240242.

Roberts, JE; Williams, K; Dallas, J; Eckert, M; Huie, L; Smitherman, E; Soulsby, WD; Zhao, Y; Son, MB F; Abel, N; Delnay, N; Dempsey, V; DeSantis, E; Dickson, T. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. The Journal of rheumatology. 2023; 50:1047-1057.

Smitherman, EA; Chahine, RA; Beukelman, T; Lewandowski, LB; Rahman, AK M F; Wenderfer, SE; Curtis, JR; Hersh, AO; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75:1553-1562.

De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). 2023; 110-111.

Ruperto, N; Foeldvari, I; Alexeeva, E; Aktay Ayaz, N; Schulert, G; Özen, S; Popov, A; Ramanan, A; Scott, C; Sozeri, B; Pricop, L; Lovell, DJ; Martini, A; Brunner, H. POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. 2023; 379.2-37380.

De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; Asnaghi, V; Ballabio, M; Jacqmin, P; De Min, C. Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Kuhn, KA; Stahly, A; Konig, MF; Carandang, K; Herndon, C; Backman, C; Callahan, LF; Schulert, G; Fraenkel, L; Ogdie, A. Impact of the COVID-19 Pandemic on Early Career Investigators in Rheumatology: Recommendations to Address Challenges to Early Research Careers. Arthritis Care and Research. 2023; 75:947-955.

Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75:983-988.

Jhaveri, R; Webb, R; Razzaghi, H; Schuchard, J; Mejias, A; Bennett, TD; Jone, PN; Thacker, D; Schulert, GS; Rogerson, C; Cogen, JD; Bailey, LC; Forrest, CB; Lee, GM; Rao, S. Can Multisystem Inflammatory Syndrome in Children Be Managed in the Outpatient Setting? An EHR-Based Cohort Study From the RECOVER Program. Journal of the Pediatric Infectious Diseases Society. 2023; 12:159-162.

Ringold, S; Dennos, AC; Kimura, Y; Beukelman, T; Shrader, P; Phillips, TA; Kohlheim, M; Schanberg, LE; Yeung, RS M; Horton, DB; Dean, J; Dedeoglu, F; DeGuzman, M; Delnay, N. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75:715-723.

Shiff, NJ; Shrader, P; Correll, CK; Dennos, A; Phillips, T; Beukelman, T; Abel, N; Abulaban, K; Adams, A; Adams, M; Donaldson, B; Dorsey, E; Dover, S; Dowling, J. Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62:804-814.

Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; Schulert, GS. Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.

Macaraeg, M; Schulert, GS. Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis. RMD Open. 2023; 9:e002611.

Borgia, RE; Gurka, MJ; Filipp, SL; Elder, M; Cardel, M; Shiff, NJ; Abel, N; Abulaban, K; Adams, A; Adams, M; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.

Smitherman, EA; Chahine, RA; Bitencourt, N; Rahman, AK M F; Lawson, EF; Chang, JC; Abel, N; Abulaban, K; Adams, A; Adams, M; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2023; 50:98-106.

Brunner, HI; Foeldvari, I; Alexeeva, E; Ayaz, NA; Calvo Penades, I; Kasapcopur, O; Chasnyk, VG; Hufnagel, M; Zuber, Z; Schulert, G; Pricop, L; Martini, A; Lovell, D; Ruperto, N. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.

Bahakel, H; Murphy, CR; Frenck, RW; Grimley, M; Phillips, C; Schulert, G; Spearman, P; Courter, JD; Paulsen, GC; Danziger-Isakov, LA. 1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Open Forum Infectious Diseases. 2022; 9:ofac492.958.

Soulsby, WD; Balmuri, N; Cooley, V; Gerber, LM; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2022; 20:18.

Neely, J; Ardalan, K; Huber, A; Kim, S; Abel, N; Abulaban, K; Adams, A; Adams, M; Agbayani, R; Aiello, J; Dickson, T; Dingle, J; Donaldson, B; Dorsey, E. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology Online Journal. 2022; 20:50.

Bahakel, H; Murphy, C; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Haslam, DB; Phillips, CL; Courter, J; Spearman, P; Schulert, G; Danziger-Isakov, L. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. The Pediatric Infectious Disease Journal. 2022; 41:985-988.

Hahn, T; Daymont, C; Beukelman, T; Groh, B; Hays, K; Bingham, CA; Scalzi, L; Abel, N; Abulaban, K; Adams, A; Delnay, N; Dempsey, V; DeSantis, E; Dickson, T. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2022; 20:107.

Son, MB F; Berbert, L; Young, C; Dallas, J; Newhams, M; Chen, S; Ardoin, SP; Basiaga, ML; Canny, SP; Crandall, H; Zambrano, LD; Campbell, AP; Patel, MM; Randolph, AG. Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children. JAMA network open. 2022; 5:e2241622.

Schulert, GS. The Big Bad Wolf: Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus. The Journal of rheumatology. 2022; 49:1082-1084.

Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; Goldbach-Mansky, R; Khatri, P; Mellins, ED; Canna, SW. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Kernan, KF; Schulert, GS; Seo, P; Mudano, AS; Turner, AS; Karp, DR; Mehta, JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis and Rheumatology. 2022; 74:e1-e20.

Verweyen, EL; Schulert, GS. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology. 2022; 61:926-935.

Dave, I; Estroff, B; Gergely, T; Rostad, CA; Ponder, LA; McCracken, C; Prahalad, S; Abel, N; Abulaban, K; Adams, A; DeSantis, E; Dickson, T; Dingle, J; Donaldson, B. Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. The Journal of rheumatology. 2021; 48:1856-1862.

Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; Abel, N; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology Online Journal. 2021; 19:131.

Schulert, GS; Blum, SA; Cron, RQ. Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Current Opinion in Pediatrics. 2021; 33:549-555.

Balmuri, N; Soulsby, WD; Cooley, V; Gerber, L; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; DeGuzman, M; Delnay, N; Dempsey, V; DeSantis, E. Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology Online Journal. 2021; 19:122.

Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; Altaye, M; Holland, GN. S100 proteins, cytokines, and chemokines as tear biomarkers in children with juvenile idiopathic arthritis-associated uveitis. Ocular Immunology and Inflammation (Informa). 2021; 29:1616-1620.

Erkens, R; Esteban, Y; Towe, C; Schulert, G; Vastert, S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheumatic Disease Clinics of North America. 2021; 47:585-606.

Kimura, Y; Schanberg, LE; Tomlinson, GA; Riordan, ME; Dennos, AC; Del Gaizo, V; Murphy, KL; Weiss, PF; Natter, MD; Feldman, BM; Rosolowski, B; Ruth, N; Schikler, K; Sepulveda, A. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.

Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; Abel, N; Abulaban, K; Adams, A; Adams, M; Dempsey, V; DeSantis, E; Dickson, T; Dingle, J. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.

Gao, DK; Salomonis, N; Henderlight, M; Woods, C; Thakkar, K; Grom, AA; Thornton, S; Jordan, MB; Wikenheiser-Brokamp, KA; Schulert, GS. IFN-γ is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome. JCI insight. 2021; 6:e147593.

Walsh, KB; Zimmerman, KD; Zhang, X; Demel, SL; Luo, Y; Langefeld, CD; Wohleb, E; Schulert, G; Woo, D; Adeoye, O. miR-181a Mediates Inflammatory Gene Expression After Intracerebral Hemorrhage: An Integrated Analysis of miRNA-seq and mRNA-seq in a Swine ICH Model. Journal of Molecular Neuroscience. 2021; 71:1802-1814.

Rodriguez-Smith, JJ; Verweyen, EL; Clay, GM; Esteban, YM; de Loizaga, SR; Baker, EJ; Do, T; Dhakal, S; Lang, SM; Grom, AA; Grier, D; Schulert, GS. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. The Lancet. Rheumatology. 2021; 3:e574-e584.

Mannion, ML; Xie, F; Horton, DB; Ringold, S; Correll, CK; Dennos, A; Beukelman, T; Abel, N; Abulaban, K; Adams, A; Dingle, J; Donaldson, B; Dorsey, E; Dover, S. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. The Journal of rheumatology. 2021; 48:1322-1329.

Verweyen, EL; Pickering, A; Grom, AA; Schulert, GS. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology. 2021; 73:1334-1340.

Rumsey, DG; Lougee, A; Matsouaka, R; Collier, DH; Schanberg, LE; Schenfeld, J; Shiff, NJ; Stoll, ML; Stryker, S; Weiss, PF; Dean, J; Dedeoglu, F; DeGuzman, M; Delnay, N. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.

Schulert, GS. The IL-18/IFNγ axis in systemic JIA and MAS-new answers, more questions. Rheumatology. 2021; 60:3045-3047.

Ombrello, MJ; Schulert, GS. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. Translational Research: the journal of laboratory and clinical medicine. 2021; 232:1-12.

Cheung, P; Schaffert, S; Chang, SE; Dvorak, M; Donato, M; Macaubas, C; Foecke, MH; Li, TM; Zhang, L; Coan, JP; Mellins, ED; Khatri, P; Utz, PJ; Kuo, AJ. Repression of CTSG, ELANE and PRTN3-mediated histone H3 proteolytic cleavage promotes monocyte-to-macrophage differentiation. Nature Immunology. 2021; 22:711-722.

Danziger-Isakov, L; Khalil, N; Divanovic, A; Frenck, R; Grimley, M; Iliopoulos, I; Marsh, R; Paulsen, G; Phillips, CL; Schulert, G; Spearman, P; Blum, S; Hui-Chin Ho, J. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. The Pediatric Infectious Disease Journal. 2021; 40:e234-e235.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Ferris, A; Kernan, KF; Schulert, GS; Mudano, AS; Turner, AS; Karp, DR; Mehta, JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis and Rheumatology. 2021; 73:e13-e29.

Murphy, ME; Clay, G; Danziger-Isakov, L; Schulert, G; Paulsen, GC. Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. Current Opinion in Pediatrics. 2021; 33:129-135.

King, CD; Boggero, IA; Schulert, GS; Pickerill, HM; Cole, S. Preliminary evidence for conserved transcriptional response to adversity in adults with temporomandibular disorder. Pain Reports. 2021; 6:e874.

Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology Online Journal. 2020; 18:7.

Cron, RQ; Schulert, GS; Tattersall, RS. Defining the scourge of COVID-19 hyperinflammatory syndrome. The Lancet. Rheumatology. 2020; 2:e727-e729.

Amarilyo, G; Rothman, D; Manthiram, K; Edwards, KM; Li, SC; Marshall, GS; Yildirim-Toruner, C; Haines, K; Ferguson, PJ; Lionetti, G; Stern, S; Durrant, K; Butbul, Y; Hausmann, J. Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology research alliance (CARRA) PFAPA work group. Pediatric Rheumatology Online Journal. 2020; 18:31.

Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; Mitchell, J; de Jesus, AA; Schulert, GS; Goldbach-Mansky, R. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). Journal of Allergy and Clinical Immunology. 2020; 146:1204-1208.e6.

Henderson, LA; Canna, SW; Friedman, KG; Gorelik, M; Lapidus, SK; Bassiri, H; Behrens, EM; Ferris, A; Kernan, KF; Schulert, GS; Mudano, AS; Turner, AS; Karp, DR; Mehta, JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis and Rheumatology. 2020; 72:1791-1805.

Schulert, GS. The Storm Beneath the Storm: MAS-HLH in Inflammatory Myopathies. The Journal of rheumatology. 2020; 47:1461-1463.

Schulert, GS. Can tocilizumab calm the cytokine storm of COVID-19?. The Lancet. Rheumatology. 2020; 2:e449-e451.

Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; DeBenedetti, F; Grom, A; Participants, N. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology Online Journal. 2020; 18:53.

Henderson, LA; Canna, SW; Schulert, GS; Volpi, S; Lee, PY; Kernan, KF; Caricchio, R; Mahmud, S; Hazen, MM; Halyabar, O; De Benedetti, F; Behrens, EM; Cron, RQ; Nigrovic, PA. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis and Rheumatology. 2020; 72:1059-1063.

Schulert, GS; Cron, RQ. The genetics of macrophage activation syndrome. Genes and Immunity. 2020; 21:169-181.

de Jesus, AA; Hou, Y; Brooks, S; Malle, L; Biancotto, A; Huang, Y; Calvo, KR; Marrero, B; Moir, S; Oler, AJ; van Royen-Kerkhof, A; Muskardin, TW; Canna, SW; Goldbach-Mansky, R. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. The Journal of Clinical Investigation. 2020; 130:1669-1682.

Verweyen, E; Holzinger, D; Weinhage, T; Hinze, C; Wittkowski, H; Pickkers, P; Albeituni, S; Verbist, K; Nichols, KE; Schulert, G; Grom, A; Foell, D; Kessel, C. Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. American Journal of Respiratory and Critical Care Medicine. 2020; 201:526-539.

Ferrara, G; Giani, T; Lieberman, SM; Kremer, C; Hong, S; Indolfi, G; Schulert, G; Cron, RQ; Mannion, ML; Lapidus, S; Armbrust, W; Gonzales, E; Jacquemin, E; Koné-Paut, I; Cimaz, R. Alagille Syndrome and Chronic Arthritis: An International Case Series. The Journal of Pediatrics. 2020; 218:228-230.e1.

Abid, Q; Best Rocha, A; Larsen, CP; Schulert, G; Marsh, R; Yasin, S; Patty-Resk, C; Valentini, RP; Adams, M; Baracco, R. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI). American Journal of Kidney Diseases. 2020; 75:287-290.

Yasin, S; Solomon, K; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Schiffrin, E; Sleight, A; Grom, AA; Schulert, GS. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020; 59:442-445.

Yasin, S; Fall, N; Brown, RA; Henderlight, M; Canna, SW; Girard-Guyonvarc'h, C; Gabay, C; Grom, AA; Schulert, GS. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology. 2020; 59:361-366.

Lee, PY; Schulert, GS; Canna, SW; Huang, Y; Sundel, J; Li, Y; Hoyt, KJ; Blaustein, RB; Wactor, A; Do, T; Hershfield, MS; Son, MB; Henderson, LA; Nigrovic, PA. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2020; 79:225-231.